There is a way to access REGORAFINIB (STIVARGA) OR OTHERS in Canada.
Health Canada’s Special Access Programme (SAP) provides access to nonmarketed drugs for practitioners treating patients with serious or life-threatening conditions when conventional therapies have failed, are unsuitable, or unavailable. The SAP authorizes a manufacturer to sell a drug that cannot otherwise be sold or distributed in Canada. Drugs considered for release by the SAP include pharmaceutical, biologic, and radio-pharmaceutical products not approved for sale in Canada.
Scroll down on the SAP chart to “regorafenib” OR THE MEDICATION YOU ARE LOOKING FOR and you will find the necessary contact information.